^
No biomarker
Prostate Cancer
enzalutamide
Sensitive
:
A1
Astellas Press Release - 3d
No biomarker
Prostate Cancer
apalutamide
Sensitive
:
A1
J Clin Oncol - 1wk
NEIL3 deletion
Prostate Cancer
enzalutamide
Resistant
:
D
Int J Mol Sci - 3wk
No biomarker
Prostate Cancer
histrelin acetate
Sensitive
:
A1
No biomarker
Prostate Cancer
cabazitaxel
Sensitive
:
A1
BRCA2 mutation
Prostate Cancer
olaparib
Sensitive
:
A1
BRCA1 mutation
Prostate Cancer
olaparib
Sensitive
:
A1
No biomarker
Prostate Cancer
relugolix
Sensitive
:
A1
No biomarker
Prostate Cancer
docetaxel + prednisone
Sensitive
:
A1
No biomarker
Prostate Cancer
abiraterone acetate
Sensitive
:
A1
No biomarker
Prostate Cancer
degarelix
Sensitive
:
A1
ATM mutation
Prostate Cancer
olaparib
Sensitive
:
A1
No biomarker
Prostate Cancer
darolutamide
Sensitive
:
A1
BRCA1 mutation
Prostate Cancer
rucaparib
Sensitive
:
A1
BRCA2 mutation
Prostate Cancer
rucaparib
Sensitive
:
A1
HRD
Prostate Cancer
olaparib
Sensitive
:
A1
No biomarker
Prostate Cancer
zoledronic acid
Sensitive
:
A1
No biomarker
Prostate Cancer
triptorelin
Sensitive
:
A1
MSI-H/dMMR
Prostate Cancer
pembrolizumab
Sensitive
:
A2
No biomarker
Prostate Cancer
mitoxantrone
Sensitive
:
A2
No biomarker
Prostate Cancer
etoposide IV
Sensitive
:
A2
No biomarker
Prostate Cancer
atezolizumab
Sensitive
:
A2
No biomarker
Prostate Cancer
docetaxel
Sensitive
:
A2
CDK12 mutation
Prostate Cancer
olaparib
Sensitive
:
A2
PALB2 mutation
Prostate Cancer
olaparib
Sensitive
:
A2
CHEK2 mutation
Prostate Cancer
olaparib
Sensitive
:
A2
CHEK1 mutation
Prostate Cancer
olaparib
Sensitive
:
A2
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our